Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T-cells for treatment of multiple myeloma
Sign Up to like & getrecommendations! Published in 2020 at "Leukemia"
DOI: 10.1038/s41375-020-0951-5
Abstract: Chimeric antigen receptor (CAR) T-cell therapy remains limited to select centers that can carefully monitor adverse events. To broaden use of CAR T cells in community clinics and in a frontline setting, we developed a… read more here.
Keywords: treatment multiple; myeloma; multiple myeloma; car cells ... See more keywords
Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma
Sign Up to like & getrecommendations! Published in 2025 at "Leukemia"
DOI: 10.1038/s41375-025-02757-6
Abstract: Introduction: Despite potent efficacy of bispecific antibodies against the B-cell maturation antigen (BCMA) in multiple myeloma (MM), primary resistance may occur in as many as 40% of patients. Known resistance mechanisms include antigen loss, epigenetic… read more here.
Keywords: bcma; anti bcma; sbcma; plasmapheresis ... See more keywords
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study
Sign Up to like & getrecommendations! Published in 2025 at "Blood Cancer Journal"
DOI: 10.1038/s41408-025-01365-y
Abstract: Dear Editor, Even at the era of T-cell redirecting therapies, patients with relapsed or refractory multiple myeloma (RRMM) presenting extramedullary disease (EMD) and/or high risk cytogenetic abnormalities (HRCA) constitute a particularly challenging sub-group with lower… read more here.
Keywords: prior anti; anti bcma; rrmm; bcma cd3 ... See more keywords
Leukoreduction filter derived NK cells offer a promising source for off the shelf CAR NK cell immunotherapy
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-97584-1
Abstract: Immunotherapy employing natural killer (NK) cells has emerged as a transformative approach to treating hematological malignancies. The reprogramming of NK cells by incorporating a chimeric antigen receptor (CAR) equipped with potent signaling domains has demonstrated… read more here.
Keywords: anti bcma; immunotherapy; bcma car; culture ... See more keywords
Abstract 1322: A cryopreserved allogeneic anti-BCMA CAR-NK cellular therapy exhibits both innate and CAR-mediated MM cell killing in vitro and in vivo
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-1322
Abstract: Introduction Multiple myeloma (MM) is the second most prevalent hematopoietic malignancy with an overall 5-year survival rate of 58%. B cell maturation antigen (BCMA) is selectively expressed on normal and malignant plasma cells, making it… read more here.
Keywords: anti bcma; therapy; bcma car; car ... See more keywords
Abstract P31: Design and Development of a Novel Anti-BCMA.ECD Antibody for Live Cell Therapy in Multiple Myeloma (MM)
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.fcs2024-p31
Abstract: Multiple myeloma is characterized by the expansion of malignant plasma cells in the bone marrow (BM), which is associated with excessive production of monoclonal immunoglobulins in blood and urine in patients. The addition of monoclonal… read more here.
Keywords: bcma; anti bcma; therapy; bcma ecd ... See more keywords
Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-131892
Abstract: Background: Multiple myeloma remains an incurable malignancy of plasma cells. Adoptive transfer of chimeric antigen receptor (CAR)-expressing T cells is a promising new therapy for hematologic malignancies. B-cell maturation antigen (BCMA) is a protein that… read more here.
Keywords: anti bcma; equity ownership; dar;
Debulking Conventional Chemotherapy before Treatment By Anti-BCMA Bispecific Antibody in Extramedullary and/or High Tumor Burden Relapsed/Refractory Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-203778
Abstract: Background. New immunotherapies have improved response rates and survival in relapse/refractory multiple myeloma (RRMM) setting. However, patients with extramedullary disease (EMD) and/or high tumor burden continue to have poor response rates and inferior survival, representing… read more here.
Keywords: anti bcma; response; chemotherapy; tumor burden ... See more keywords
Steric Hindrance By APRIL in Binding of BCMA-Directed Bispecific Antibodies: A Novel Refractory Mechanism of BCMA-Directed Immunotherapies in Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-204524
Abstract: Multiple myeloma (MM) cells preferentially reside and grow in the bone marrow while activating osteoclasts (OCs). The aberrantly activated OCs induce bone lysis and support MM-cell growth and survival, leading to forming the vicious cycle… read more here.
Keywords: bcma; anti bcma; bcma directed; directed immunotherapies ... See more keywords
Outcomes of Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Therapies after Exposure to T-Cell Redirected or BCMA-Targeted Novel Immunotherapies
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-207919
Abstract: Background: Promising results have been seen in heavily pretreated myeloma patients (pts) after the use of novel T-cell redirected bispecifics targeting BCMA, GPRC5d or FcRH5 or anti-BCMA targeted immunotherapies (bispecifics, ADC or CAR T-cell products).… read more here.
Keywords: bcma; anti bcma; therapy; cell ... See more keywords
A Single-Center, Single-Arm, Phase I Clinical Trial of Anti-BCMA/GPRC5D Bispecific CAR T-Cells in Patients with Refractory and Relapsed Multiple Myeloma with Extramedullary Disease
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-210226
Abstract: Background: Despite the promising outcomes of chimeric antigen receptor (CAR) T-cell therapy in treating relapsed or refractory multiple myeloma (RRMM), addressing extramedullary disease (EMD) in this context remains a therapeutic challenge. This study aimed to… read more here.
Keywords: disease; anti bcma; gprc5d bispecific; bispecific car ... See more keywords